Tavio Capital LLC cut its stake in shares of Humana Inc. (NYSE:HUM) by 65.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 73,098 shares of the insurance provider’s stock after selling 136,421 shares during the period. Humana makes up approximately 8.8% of Tavio Capital LLC’s portfolio, making the stock its 6th largest position. Tavio Capital LLC owned about 0.05% of Humana worth $17,589,000 as of its most recent filing with the SEC.
Other large investors have also made changes to their positions in the company. Guardian Life Insurance Co. of America boosted its position in Humana by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 575 shares of the insurance provider’s stock valued at $119,000 after buying an additional 4 shares in the last quarter. Independent Portfolio Consultants Inc. boosted its position in shares of Humana by 22.1% in the second quarter. Independent Portfolio Consultants Inc. now owns 519 shares of the insurance provider’s stock worth $125,000 after buying an additional 94 shares during the period. Point72 Asia Hong Kong Ltd bought a new position in shares of Humana during the first quarter worth about $128,000. Westbourne Investment Advisors Inc. bought a new position in shares of Humana during the second quarter worth about $205,000. Finally, Hengehold Capital Management LLC bought a new position in shares of Humana during the second quarter worth about $209,000. Institutional investors and hedge funds own 99.13% of the company’s stock.
Humana Inc. (NYSE HUM) opened at 247.28 on Friday. The firm has a market capitalization of $35.74 billion, a price-to-earnings ratio of 20.34 and a beta of 0.91. The stock has a 50 day moving average of $241.05 and a 200 day moving average of $224.57. Humana Inc. has a 12-month low of $163.50 and a 12-month high of $255.27.
The business also recently announced a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Tuesday, August 29th will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, September 28th. This represents a $1.60 annualized dividend and a yield of 0.65%. Humana’s dividend payout ratio (DPR) is currently 13.06%.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/19/humana-inc-nysehum-position-lowered-by-tavio-capital-llc-updated-updated.html.
A number of research analysts have recently weighed in on the stock. UBS AG reissued a “neutral” rating and set a $250.00 price objective (up from $237.00) on shares of Humana in a research note on Wednesday, August 9th. Zacks Investment Research cut shares of Humana from a “buy” rating to a “hold” rating in a research note on Monday, April 24th. Cowen and Company reissued a “buy” rating and set a $230.00 price objective on shares of Humana in a research note on Friday, July 14th. BidaskClub upgraded shares of Humana from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $223.00 price target (up previously from $200.00) on shares of Humana in a report on Thursday, August 3rd. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $244.35.
In other Humana news, VP Heidi S. Margulis sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $231.96, for a total transaction of $347,940.00. Following the sale, the vice president now directly owns 8,150 shares in the company, valued at approximately $1,890,474. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Brian P. Leclaire sold 4,971 shares of the firm’s stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the sale, the senior vice president now owns 14,258 shares in the company, valued at $3,421,920. The disclosure for this sale can be found here. Insiders have sold a total of 41,406 shares of company stock worth $10,355,086 over the last 90 days. Corporate insiders own 0.80% of the company’s stock.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
What are top analysts saying about Humana Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Humana Inc. and related companies.